Cat. No. | Product name | CAS No. |
DC66675 | VIB9600 Featured | |
DC66676 |
Cevostamab
Featured
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells. |
2249888-53-5 |
DC66677 | DFRF4539A Featured | |
DC66678 |
Rozanolixizumab
Featured
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases. |
1584645-37-3 |
DC66679 | STX-100 Featured | |
DC66680 |
Abrilumab
Featured
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD). |
1342290-43-0 |
DC66681 |
Batoclimab
Featured
Batoclimab is a human anti-FcRn monoclonal antibody. Batoclimab can be used for the research of autoimmune diseases mediated by pathogenic IgG antibodies. |
2187430-05-1 |
DC66682 | Anti-FGF19 Reference Antibody (1A6) Featured | |
DC66683 | HuGAL-F2 Featured | |
DC66684 |
Burosumab
Featured
Burosumab is a human fibroblast growth factor 23 (FGF23) neutralizing antibody that can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia. |
1610833-03-8 |
DC66685 | Lilly patent anti-FGFR-1 Featured | |
DC66686 |
Aprutumab
Featured
Aprutumab (BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research. |
1634620-63-5 |
DC66687 |
Bemarituzumab
Featured
Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research. |
1952272-74-0 |
DC66688 |
Vofatamab
Featured
Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC). |
1312305-12-6 |
DC66689 | U3-1784 Featured | |
DC66690 | Radretumab Featured | |
DC66691 | L19TNF Featured | |
DC66692 |
Rosopatamab
Featured
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 (177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency. |
2260767-49-3 |
DC66693 |
Pelgifatamab
Featured
Pelgifatamab (BAY-2315497) is a prostate-specific membrane antigen (PSMA) antibody. Pelgifatamab can be covalently linked to a binding moiety of 225Ac and used for metastatic castration-resistant prostate cancer (mCRPC) research. |
2414550-93-7 |
DC66694 |
Mirvetuximab
Featured
Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research. |
1453084-36-0 |
DC66695 |
Cofrogliptin
Featured
Cofrogliptin (HSK7653) (compound 2), a tetrahydropyran derivative, is a potent oral dipeptidyl aminopeptidase 4 (DPP-4) inhibitor with Long-acting antidiabetic efficacy. Cofrogliptin (compound 2) has a great potential for type 2 diabetes mellitus (T2DM) . |
1844874-26-5 |
DC66696 |
(R)-2-Thioxothiazolidine-4-carboxylic acid-13C3
Featured
(R)-2-Thioxothiazolidine-4-carboxylic acid-13C3 is the 13C-labeled (R)-2-Thioxothiazolidine-4-carboxylic acid. Radioactive isotopes labeled compounds can be used in metabolic analysis, allowing the movement of individual atoms to be precisely tracked and quantified. |
2704345-00-4 |